2018-HUAN-68180 | |
Protein N-terminal methyltransferase 1 (NTMT1) plays an important role in regulating cell mitosis, chromatin interactions, and DNA repair. NTMT1 is over-expressed in cancer patient tissues including the head and neck, colorectal, malignant melanoma, compared to normal tissue. Knockdown of NTMT1 promotes hypersensitivity of breast cancer cell lines to double-strand DNA breaks (DSBs) by etoposide and gamma irradiation. This knowledge has made NTMT1 an important anticancer target. Currently, there are no specific cell-potent probes available for NTMT1. There is a need for a new technology that can target the NTMT1 protein. Researchers at Purdue University have developed new potent inhibitors for the protein NTMT. The inhibitor exhibited high selectivity to NTMT1/2 over a panel of 41 methyltransferases. These chemical compounds are novel because they are amenable for cell-based studies. They may be further optimized for animal studies. This technology is more stable and cell-permeable than existing solutions. This technology could open the door for elucidate the pharmacological functions of protein NTMT1. Advantages: -Amenable for cell based studies -Displays selective inhibition for NTMT1 -May be used for animal studies Potential Applications: -Cell based studies -Animal studies |
|
|
|
May 16, 2019
Utility Patent
United States
(None)
(None)
May 17, 2018
Provisional-Patent
United States
(None)
(None)
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |